Laurent Meijer, PhD, University of Paris 1983 - Publications

Affiliations: 
Cell Cycle Group CNRS, Station Biologique de Roscoff, Roscoff, Bretagne, France 
Area:
http://www.biomedexperts.com/Profile.bme/924584/Laurent_Meijer
Website:
http://www.esi-topics.com/erf/2004/august04-LaurentMeijer.html

164 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Deau E, Lindberg MF, Miege F, Roche D, George N, George P, Krämer A, Knapp S, Meijer L. Leucettinibs, a Class of DYRK/CLK Kinase Inhibitors Inspired by the Marine Sponge Natural Product Leucettamine B. Journal of Medicinal Chemistry. PMID 37487467 DOI: 10.1021/acs.jmedchem.3c00884  0.398
2023 Meijer L, Dube F, Guerrier P. Trifluoperazine-Sensitive Step during Sea Urchin, Echiuroid and Pelecypod Egg Activation: (trifluoperazine/calmodulin/calcium/maturation/fertilization). Development, Growth & Differentiation. 25: 469-475. PMID 37282030 DOI: 10.1111/j.1440-169X.1983.00469.x  0.526
2023 Lindberg MF, Deau E, Arfwedson J, George N, George P, Alfonso P, Corrionero A, Meijer L. Comparative Efficacy and Selectivity of Pharmacological Inhibitors of DYRK and CLK Protein Kinases. Journal of Medicinal Chemistry. PMID 36876904 DOI: 10.1021/acs.jmedchem.2c02068  0.42
2022 Sunkari YK, Meijer L, Flajolet M. The protein kinase CK1: Inhibition, activation, and possible allosteric modulation. Frontiers in Molecular Biosciences. 9: 916232. PMID 36090057 DOI: 10.3389/fmolb.2022.916232  0.392
2021 Tahtouh T, Durieu E, Villiers B, Bruyère C, Nguyen TL, Fant X, Ahn KH, Khurana L, Deau E, Lindberg MF, Sévère E, Miege F, Roche D, Limanton E, L'Helgoual'ch JM, ... ... Meijer L, et al. Structure-Activity Relationship in the Leucettine Family of Kinase Inhibitors. Journal of Medicinal Chemistry. PMID 34928152 DOI: 10.1021/acs.jmedchem.1c01141  0.405
2021 Bourahla K, Guihéneuf S, Limanton E, Paquin L, Le Guével R, Charlier T, Rahmouni M, Durieu E, Lozach O, Carreaux F, Meijer L, Bazureau JP. Design and Microwave Synthesis of New (5) 5-Arylidene-2-thioxo-1,3-thiazolinidin-4-one and (5) 2-Amino-5-arylidene-1,3-thiazol-4(5)-one as New Inhibitors of Protein Kinase DYRK1A. Pharmaceuticals (Basel, Switzerland). 14. PMID 34832868 DOI: 10.3390/ph14111086  0.305
2021 Lindberg MF, Meijer L. Dual-Specificity, Tyrosine Phosphorylation-Regulated Kinases (DYRKs) and cdc2-Like Kinases (CLKs) in Human Disease, an Overview. International Journal of Molecular Sciences. 22. PMID 34205123 DOI: 10.3390/ijms22116047  0.329
2020 Loidreau Y, Dubouilh-Benard C, Nourrisson MR, Loaëc N, Meijer L, Besson T, Marchand P. Exploring Kinase Inhibition Properties of 9-pyrimido[5,4-]- and [4,5-]indol-4-amine Derivatives. Pharmaceuticals (Basel, Switzerland). 13. PMID 32397570 DOI: 10.3390/ph13050089  0.349
2019 Fruit C, Couly F, Bhansali R, Rammohan M, Lindberg MF, Crispino JD, Meijer L, Besson T. Biological Characterization of 8-Cyclopropyl-2-(pyridin-3-yl)thiazolo[5,4-]quinazolin-9(8)-one, a Promising Inhibitor of DYRK1A. Pharmaceuticals (Basel, Switzerland). 12. PMID 31861110 DOI: 10.3390/Ph12040185  0.34
2019 Lechner C, Flaßhoff M, Falke H, Preu L, Loaëc N, Meijer L, Knapp S, Chaikuad A, Kunick C. []-Annulated Halogen-Substituted Indoles as Potential DYRK1A Inhibitors. Molecules (Basel, Switzerland). 24. PMID 31766108 DOI: 10.3390/molecules24224090  0.376
2018 Couly F, Harari M, Dubouilh-Benard C, Bailly L, Petit E, Diharce J, Bonnet P, Meijer L, Fruit C, Besson T. Development of Kinase Inhibitors via Metal-Catalyzed C⁻H Arylation of 8-Alkyl-thiazolo[5,4-]-quinazolin-9-ones Designed by Fragment-Growing Studies. Molecules (Basel, Switzerland). 23. PMID 30158487 DOI: 10.3390/molecules23092181  0.341
2018 Walter A, Chaikuad A, Helmer R, Loaëc N, Preu L, Ott I, Knapp S, Meijer L, Kunick C. Molecular structures of cdc2-like kinases in complex with a new inhibitor chemotype. Plos One. 13: e0196761. PMID 29723265 DOI: 10.1371/journal.pone.0196761  0.384
2018 Meine R, Becker W, Falke H, Preu L, Loaëc N, Meijer L, Kunick C. Indole-3-Carbonitriles as DYRK1A Inhibitors by Fragment-Based Drug Design. Molecules (Basel, Switzerland). 23. PMID 29364148 DOI: 10.3390/molecules23020064  0.349
2017 Loaëc N, Attanasio E, Villiers B, Durieu E, Tahtouh T, Cam M, Davis RA, Alencar A, Roué M, Bourguet-Kondracki ML, Proksch P, Limanton E, Guiheneuf S, Carreaux F, Bazureau JP, ... ... Meijer L, et al. Marine-Derived 2-Aminoimidazolone Alkaloids. Leucettamine B-Related Polyandrocarpamines Inhibit Mammalian and Protozoan DYRK & CLK Kinases. Marine Drugs. 15. PMID 29039762 DOI: 10.3390/Md15100316  0.393
2017 Nguyen TL, Fruit C, Hérault Y, Meijer L, Besson T. Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature. Expert Opinion On Therapeutic Patents. 1-17. PMID 28766366 DOI: 10.1080/13543776.2017.1360285  0.398
2017 Karthikeyan C, Jharia P, Waiker DK, Nusbaum AC, Amawi H, Kirwen EM, Christman R, Arudra SKC, Meijer L, Tiwari AK, Trivedi P. N-(1H-Pyrazol-3-yl)quinazolin-4-amines as a novel class of casein kinase 1δ/ε inhibitors: Synthesis, biological evaluation and molecular modeling studies. Bioorganic & Medicinal Chemistry Letters. PMID 28487075 DOI: 10.1016/j.bmcl.2017.04.080  0.358
2016 Walter A, Chaikuad A, Loaëc N, Preu L, Knapp S, Meijer L, Kunick C, Koch O. Identification of CLK1 Inhibitors by a Fragment-linking Based Virtual Screening. Molecular Informatics. PMID 28000414 DOI: 10.1002/minf.201600123  0.381
2016 Bendjeddou LZ, Loaëc N, Villiers B, Prina E, Späth GF, Galons H, Meijer L, Oumata N. Exploration of the imidazo[1,2-b]pyridazine scaffold as a protein kinase inhibitor. European Journal of Medicinal Chemistry. 125: 696-709. PMID 27721154 DOI: 10.1016/j.ejmech.2016.09.064  0.344
2016 Labrière C, Lozach O, Blairvacq M, Meijer L, Guillou C. Further investigation of Paprotrain: Towards the conception of selective and multi-targeted CNS kinase inhibitors. European Journal of Medicinal Chemistry. 124: 920-934. PMID 27676471 DOI: 10.1016/J.Ejmech.2016.08.069  0.354
2016 Zeinyeh W, Esvan YJ, Nauton L, Loaëc N, Meijer L, Théry V, Anizon F, Giraud F, Moreau P. Synthesis and preliminary in vitro kinase inhibition evaluation of new diversely substituted pyrido[3,4-g]quinazoline derivatives. Bioorganic & Medicinal Chemistry Letters. PMID 27469128 DOI: 10.1016/j.bmcl.2016.07.032  0.362
2016 Esvan YJ, Zeinyeh W, Boibessot T, Nauton L, Théry V, Knapp S, Chaikuad A, Loaëc N, Meijer L, Anizon F, Giraud F, Moreau P. Discovery of pyrido[3,4-g]quinazoline derivatives as CMGC family protein kinase inhibitors: Design, synthesis, inhibitory potency and X-ray co-crystal structure. European Journal of Medicinal Chemistry. 118: 170-177. PMID 27128181 DOI: 10.1016/j.ejmech.2016.04.004  0.312
2015 Boulahjar R, Ouach A, Bourg S, Bonnet P, Lozach O, Meijer L, Guguen-Guillouzo C, Le Guevel R, Lazar S, Akssira M, Troin Y, Guillaumet G, Routier S. Advances in tetrahydropyrido[1,2-a]isoindolone (valmerins) series: Potent glycogen synthase kinase 3 and cyclin dependent kinase 5 inhibitors. European Journal of Medicinal Chemistry. 101: 274-87. PMID 26142492 DOI: 10.1016/J.Ejmech.2015.06.046  0.382
2015 Falke H, Chaikuad A, Becker A, Loaëc N, Lozach O, Abu Jhaisha S, Becker W, Jones PG, Preu L, Baumann K, Knapp S, Meijer L, Kunick C. 10-iodo-11H-indolo[3,2-c]quinoline-6-carboxylic acids are selective inhibitors of DYRK1A. Journal of Medicinal Chemistry. 58: 3131-43. PMID 25730262 DOI: 10.1021/jm501994d  0.333
2014 Houzé S, Hoang NT, Lozach O, Le Bras J, Meijer L, Galons H, Demange L. Several human cyclin-dependent kinase inhibitors, structurally related to roscovitine, are new anti-malarial agents. Molecules (Basel, Switzerland). 19: 15237-57. PMID 25251193 DOI: 10.3390/Molecules190915237  0.34
2014 Putey A, Fournet G, Lozach O, Perrin L, Meijer L, Joseph B. Synthesis and biological evaluation of tetrahydro[1,4]diazepino[1,2-a]indol-1-ones as cyclin-dependent kinase inhibitors. European Journal of Medicinal Chemistry. 83: 617-29. PMID 24998602 DOI: 10.1016/j.ejmech.2014.06.063  0.384
2014 Jarry M, Lecointre C, Malleval C, Desrues L, Schouft MT, Lejoncour V, Liger F, Lyvinec G, Joseph B, Loaëc N, Meijer L, Honnorat J, Gandolfo P, Castel H. Impact of meriolins, a new class of cyclin-dependent kinase inhibitors, on malignant glioma proliferation and neo-angiogenesis. Neuro-Oncology. 16: 1484-98. PMID 24891448 DOI: 10.1093/Neuonc/Nou102  0.336
2014 Waiker DK, Karthikeyan C, Poongavanam V, Kongsted J, Lozach O, Meijer L, Trivedi P. Synthesis, biological evaluation and molecular modelling studies of 4-anilinoquinazoline derivatives as protein kinase inhibitors. Bioorganic & Medicinal Chemistry. 22: 1909-15. PMID 24530227 DOI: 10.1016/J.Bmc.2014.01.044  0.322
2014 Rachidi N, Taly JF, Durieu E, Leclercq O, Aulner N, Prina E, Pescher P, Notredame C, Meijer L, Späth GF. Pharmacological assessment defines Leishmania donovani casein kinase 1 as a drug target and reveals important functions in parasite viability and intracellular infection. Antimicrobial Agents and Chemotherapy. 58: 1501-15. PMID 24366737 DOI: 10.1128/AAC.02022-13  0.351
2014 Fant X, Durieu E, Chicanne G, Payrastre B, Sbrissa D, Shisheva A, Limanton E, Carreaux F, Bazureau JP, Meijer L. cdc-like/dual-specificity tyrosine phosphorylation-regulated kinases inhibitor leucettine L41 induces mTOR-dependent autophagy: implication for Alzheimer's disease. Molecular Pharmacology. 85: 441-50. PMID 24366666 DOI: 10.1124/Mol.113.090837  0.357
2014 Delehouzé C, Godl K, Loaëc N, Bruyère C, Desban N, Oumata N, Galons H, Roumeliotis TI, Giannopoulou EG, Grenet J, Twitchell D, Lahti J, Mouchet N, Galibert MD, Garbis SD, ... Meijer L, et al. CDK/CK1 inhibitors roscovitine and CR8 downregulate amplified MYCN in neuroblastoma cells. Oncogene. 33: 5675-87. PMID 24317512 DOI: 10.1038/Onc.2013.513  0.369
2013 Guen VJ, Gamble C, Flajolet M, Unger S, Thollet A, Ferandin Y, Superti-Furga A, Cohen PA, Meijer L, Colas P. CDK10/cyclin M is a protein kinase that controls ETS2 degradation and is deficient in STAR syndrome. Proceedings of the National Academy of Sciences of the United States of America. 110: 19525-30. PMID 24218572 DOI: 10.1073/pnas.1306814110  0.303
2013 Deau E, Loidreau Y, Marchand P, Nourrisson MR, Loaëc N, Meijer L, Levacher V, Besson T. Synthesis of novel 7-substituted pyrido[2',3':4,5]furo[3,2-d]pyrimidin-4-amines and their N-aryl analogues and evaluation of their inhibitory activity against Ser/Thr kinases. Bioorganic & Medicinal Chemistry Letters. 23: 6784-8. PMID 24176400 DOI: 10.1016/j.bmcl.2013.10.019  0.322
2013 Yoshida K, Itoyama R, Yamahira M, Tanaka J, Loaëc N, Lozach O, Durieu E, Fukuda T, Ishibashi F, Meijer L, Iwao M. Synthesis, resolution, and biological evaluation of atropisomeric (aR)- and (aS)-16-methyllamellarins N: unique effects of the axial chirality on the selectivity of protein kinases inhibition. Journal of Medicinal Chemistry. 56: 7289-301. PMID 23981088 DOI: 10.1021/jm400719y  0.333
2013 Lewis CW, Taylor RG, Kubara PM, Marshall K, Meijer L, Golsteyn RM. A western blot assay to measure cyclin dependent kinase activity in cells or in vitro without the use of radioisotopes. Febs Letters. 587: 3089-95. PMID 23954627 DOI: 10.1016/j.febslet.2013.08.003  0.369
2013 Galons H, Oumata N, Gloulou O, Meijer L. Cyclin-dependent kinase inhibitors closer to market launch? Expert Opinion On Therapeutic Patents. 23: 945-63. PMID 23600454 DOI: 10.1517/13543776.2013.789861  0.356
2013 Marti G, Eparvier V, Morleo B, Le Ven J, Apel C, Bodo B, Amand S, Dumontet V, Lozach O, Meijer L, Guéritte F, Litaudon M. Natural aristolactams and aporphine alkaloids as inhibitors of CDK1/cyclin B and DYRK1A. Molecules (Basel, Switzerland). 18: 3018-27. PMID 23467012 DOI: 10.3390/Molecules18033018  0.308
2013 Burgy G, Tahtouh T, Durieu E, Foll-Josselin B, Limanton E, Meijer L, Carreaux F, Bazureau JP. Chemical synthesis and biological validation of immobilized protein kinase inhibitory Leucettines. European Journal of Medicinal Chemistry. 62: 728-37. PMID 23454515 DOI: 10.1016/j.ejmech.2013.01.035  0.328
2013 Demange L, Abdellah FN, Lozach O, Ferandin Y, Gresh N, Meijer L, Galons H. Potent inhibitors of CDK5 derived from roscovitine: synthesis, biological evaluation and molecular modelling. Bioorganic & Medicinal Chemistry Letters. 23: 125-31. PMID 23218601 DOI: 10.1016/j.bmcl.2012.10.141  0.365
2013 Fugel W, Oberholzer AE, Gschloessl B, Dzikowski R, Pressburger N, Preu L, Pearl LH, Baratte B, Ratin M, Okun I, Doerig C, Kruggel S, Lemcke T, Meijer L, Kunick C. 3,6-Diamino-4-(2-halophenyl)-2-benzoylthieno[2,3-b]pyridine-5-carbonitriles are selective inhibitors of Plasmodium falciparum glycogen synthase kinase-3. Journal of Medicinal Chemistry. 56: 264-75. PMID 23214499 DOI: 10.1021/jm301575n  0.305
2013 Demange L, Lozach O, Ferandin Y, Hoang NT, Meijer L, Galons H. Synthesis and evaluation of new potent inhibitors of CK1 and CDK5, two kinases involved in Alzheimer's disease Medicinal Chemistry Research. 22: 3247-3258. DOI: 10.1007/s00044-012-0334-1  0.33
2012 Coulibaly WK, Paquin L, Bénié A, Bekro YA, Durieux E, Meijer L, Le Guével R, Corlu A, Bazureau JP. Synthesis of New N,N'-Bis(5-arylidene-4-oxo-4,5-dihydrothiazolin-2-yl)piperazine Derivatives Under Microwave Irradiation and Preliminary Biological Evaluation. Scientia Pharmaceutica. 80: 825-36. PMID 23264934 DOI: 10.3797/scipharm.1206-04  0.305
2012 Boulahjar R, Ouach A, Matteo C, Bourg S, Ravache M, le Guével R, Marionneau S, Oullier T, Lozach O, Meijer L, Guguen-Guillouzo C, Lazar S, Akssira M, Troin Y, Guillaumet G, et al. Novel tetrahydropyrido[1,2-a]isoindolone derivatives (valmerins): potent cyclin-dependent kinase/glycogen synthase kinase 3 inhibitors with antiproliferative activities and antitumor effects in human tumor xenografts. Journal of Medicinal Chemistry. 55: 9589-606. PMID 23083119 DOI: 10.1021/Jm3008536  0.373
2012 Tahtouh T, Elkins JM, Filippakopoulos P, Soundararajan M, Burgy G, Durieu E, Cochet C, Schmid RS, Lo DC, Delhommel F, Oberholzer AE, Pearl LH, Carreaux F, Bazureau JP, Knapp S, ... Meijer L, et al. Selectivity, cocrystal structures, and neuroprotective properties of leucettines, a family of protein kinase inhibitors derived from the marine sponge alkaloid leucettamine B. Journal of Medicinal Chemistry. 55: 9312-30. PMID 22998443 DOI: 10.1021/jm301034u  0.36
2012 N'gompaza-Diarra J, Bettayeb K, Gresh N, Meijer L, Oumata N. Synthesis and biological evaluation of selective and potent cyclin-dependent kinase inhibitors. European Journal of Medicinal Chemistry. 56: 210-6. PMID 22982525 DOI: 10.1016/J.Ejmech.2012.08.033  0.415
2012 Nguyen TB, Lozach O, Surpateanu G, Wang Q, Retailleau P, Iorga BI, Meijer L, Guéritte F. Synthesis, biological evaluation, and molecular modeling of natural and unnatural flavonoidal alkaloids, inhibitors of kinases. Journal of Medicinal Chemistry. 55: 2811-9. PMID 22352892 DOI: 10.1021/Jm201727W  0.394
2012 Neagoie C, Vedrenne E, Buron F, Mérour JY, Rosca S, Bourg S, Lozach O, Meijer L, Baldeyrou B, Lansiaux A, Routier S. Synthesis of chromeno[3,4-b]indoles as Lamellarin D analogues: a novel DYRK1A inhibitor class. European Journal of Medicinal Chemistry. 49: 379-96. PMID 22305342 DOI: 10.1016/j.ejmech.2012.01.040  0.337
2012 Carassou P, Meijer L, Le Moulec S, Aoun J, Bengrine-Lefèvre L. [Cell cycle and molecular targets: CDK inhibition]. Bulletin Du Cancer. 99: 163-71. PMID 21737380 DOI: 10.1684/bdc.2011.1383  0.318
2011 Kassis P, Brzeszcz J, Bénéteau V, Lozach O, Meijer L, Le Guével R, Guillouzo C, LewiÅ„ski K, Bourg S, Colliandre L, Routier S, Mérour JY. Synthesis and biological evaluation of new 3-(6-hydroxyindol-2-yl)-5-(Phenyl) pyridine or pyrazine V-Shaped molecules as kinase inhibitors and cytotoxic agents. European Journal of Medicinal Chemistry. 46: 5416-34. PMID 21944287 DOI: 10.1016/j.ejmech.2011.08.048  0.332
2011 Giraud F, Alves G, Debiton E, Nauton L, Théry V, Durieu E, Ferandin Y, Lozach O, Meijer L, Anizon F, Pereira E, Moreau P. Synthesis, protein kinase inhibitory potencies, and in vitro antiproliferative activities of meridianin derivatives. Journal of Medicinal Chemistry. 54: 4474-89. PMID 21623630 DOI: 10.1021/jm200464w  0.363
2011 Debdab M, Carreaux F, Renault S, Soundararajan M, Fedorov O, Filippakopoulos P, Lozach O, Babault L, Tahtouh T, Baratte B, Ogawa Y, Hagiwara M, Eisenreich A, Rauch U, Knapp S, ... Meijer L, et al. Leucettines, a class of potent inhibitors of cdc2-like kinases and dual specificity, tyrosine phosphorylation regulated kinases derived from the marine sponge leucettamine B: modulation of alternative pre-RNA splicing. Journal of Medicinal Chemistry. 54: 4172-86. PMID 21615147 DOI: 10.1021/jm200274d  0.351
2011 Shengule SR, Loa-Kum-Cheung WL, Parish CR, Blairvacq M, Meijer L, Nakao Y, Karuso P. A one-pot synthesis and biological activity of ageladine A and analogues. Journal of Medicinal Chemistry. 54: 2492-503. PMID 21413800 DOI: 10.1021/Jm200039M  0.327
2011 Jain P, Flaherty PT, Yi S, Chopra I, Bleasdell G, Lipay J, Ferandin Y, Meijer L, Madura JD. Design, synthesis, and testing of an 6-O-linked series of benzimidazole based inhibitors of CDK5/p25. Bioorganic & Medicinal Chemistry. 19: 359-73. PMID 21144757 DOI: 10.1016/J.Bmc.2010.11.022  0.328
2010 Power DP, Lozach O, Meijer L, Grayson DH, Connon SJ. Concise synthesis and CDK/GSK inhibitory activity of the missing 9-azapaullones. Bioorganic & Medicinal Chemistry Letters. 20: 4940-4. PMID 20621478 DOI: 10.1016/j.bmcl.2010.06.024  0.337
2010 Sliman F, Blairvacq M, Durieu E, Meijer L, Rodrigo J, Desmaële D. Identification and structure-activity relationship of 8-hydroxy-quinoline-7-carboxylic acid derivatives as inhibitors of Pim-1 kinase. Bioorganic & Medicinal Chemistry Letters. 20: 2801-5. PMID 20363627 DOI: 10.1016/j.bmcl.2010.03.061  0.392
2010 Galons H, Oumata N, Meijer L. Cyclin-dependent kinase inhibitors: a survey of recent patent literature. Expert Opinion On Therapeutic Patents. 20: 377-404. PMID 20180621 DOI: 10.1517/13543770903524284  0.353
2009 Beauchard A, Laborie H, Rouillard H, Lozach O, Ferandin Y, Le Guével R, Guguen-Guillouzo C, Meijer L, Besson T, Thiéry V. Synthesis and kinase inhibitory activity of novel substituted indigoids. Bioorganic & Medicinal Chemistry. 17: 6257-63. PMID 19665384 DOI: 10.1016/j.bmc.2009.07.051  0.423
2009 Chioua M, Samadi A, Soriano E, Lozach O, Meijer L, Marco-Contelles J. Synthesis and biological evaluation of 3,6-diamino-1H-pyrazolo[3,4-b]pyridine derivatives as protein kinase inhibitors. Bioorganic & Medicinal Chemistry Letters. 19: 4566-9. PMID 19615897 DOI: 10.1016/j.bmcl.2009.06.099  0.311
2009 Corbel C, Haddoub R, Guiffant D, Lozach O, Gueyrard D, Lemoine J, Ratin M, Meijer L, Bach S, Goekjian P. Identification of potential cellular targets of aloisine A by affinity chromatography. Bioorganic & Medicinal Chemistry. 17: 5572-82. PMID 19596197 DOI: 10.1016/j.bmc.2009.06.024  0.325
2009 Xingi E, Smirlis D, Myrianthopoulos V, Magiatis P, Grant KM, Meijer L, Mikros E, Skaltsounis AL, Soteriadou K. 6-Br-5methylindirubin-3'oxime (5-Me-6-BIO) targeting the leishmanial glycogen synthase kinase-3 (GSK-3) short form affects cell-cycle progression and induces apoptosis-like death: exploitation of GSK-3 for treating leishmaniasis. International Journal For Parasitology. 39: 1289-303. PMID 19445946 DOI: 10.1016/j.ijpara.2009.04.005  0.319
2009 Rochais C, Duc NV, Lescot E, Sopkova-de Oliveira Santos J, Bureau R, Meijer L, Dallemagne P, Rault S. Synthesis of new dipyrrolo- and furopyrrolopyrazinones related to tripentones and their biological evaluation as potential kinases (CDKs1-5, GSK-3) inhibitors. European Journal of Medicinal Chemistry. 44: 708-16. PMID 18586356 DOI: 10.1016/j.ejmech.2008.05.011  0.368
2008 Baunbaek D, Trinkler N, Ferandin Y, Lozach O, Ploypradith P, Rucirawat S, Ishibashi F, Iwao M, Meijer L. Anticancer alkaloid lamellarins inhibit protein kinases. Marine Drugs. 6: 514-27. PMID 19172192 DOI: 10.3390/md20080026  0.427
2008 Vougogiannopoulou K, Ferandin Y, Bettayeb K, Myrianthopoulos V, Lozach O, Fan Y, Johnson CH, Magiatis P, Skaltsounis AL, Mikros E, Meijer L. Soluble 3',6-substituted indirubins with enhanced selectivity toward glycogen synthase kinase -3 alter circadian period. Journal of Medicinal Chemistry. 51: 6421-31. PMID 18816110 DOI: 10.1021/Jm800648Y  0.502
2008 Marminon C, Anizon F, Moreau P, Pfeiffer B, Pierré A, Golsteyn RM, Peixoto P, Hildebrand MP, David-Cordonnier MH, Lozach O, Meijer L, Prudhomme M. Rebeccamycin derivatives as dual DNA-damaging agents and potent checkpoint kinase 1 inhibitors. Molecular Pharmacology. 74: 1620-9. PMID 18768386 DOI: 10.1124/mol.108.049346  0.308
2008 Oumata N, Bettayeb K, Ferandin Y, Demange L, Lopez-Giral A, Goddard ML, Myrianthopoulos V, Mikros E, Flajolet M, Greengard P, Meijer L, Galons H. Roscovitine-derived, dual-specificity inhibitors of cyclin-dependent kinases and casein kinases 1. Journal of Medicinal Chemistry. 51: 5229-42. PMID 18698753 DOI: 10.1021/jm800109e  0.392
2008 Echalier A, Bettayeb K, Ferandin Y, Lozach O, Clément M, Valette A, Liger F, Marquet B, Morris JC, Endicott JA, Joseph B, Meijer L. Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin complex. Journal of Medicinal Chemistry. 51: 737-51. PMID 18232649 DOI: 10.1021/jm700940h  0.376
2008 Logé C, Testard A, Thiéry V, Lozach O, Blairvacq M, Robert JM, Meijer L, Besson T. Novel 9-oxo-thiazolo[5,4-f]quinazoline-2-carbonitrile derivatives as dual cyclin-dependent kinase 1 (CDK1)/glycogen synthase kinase-3 (GSK-3) inhibitors: synthesis, biological evaluation and molecular modeling studies. European Journal of Medicinal Chemistry. 43: 1469-77. PMID 17981370 DOI: 10.1016/j.ejmech.2007.09.020  0.349
2007 Zahler S, Tietze S, Totzke F, Kubbutat M, Meijer L, Vollmar AM, Apostolakis J. Inverse in silico screening for identification of kinase inhibitor targets. Chemistry & Biology. 14: 1207-14. PMID 18022559 DOI: 10.1016/j.chembiol.2007.10.010  0.344
2007 Bettayeb K, Tirado OM, Marionneau-Lambot S, Ferandin Y, Lozach O, Morris JC, Mateo-Lozano S, Drueckes P, Schächtele C, Kubbutat MH, Liger F, Marquet B, Joseph B, Echalier A, Endicott JA, ... ... Meijer L, et al. Meriolins, a new class of cell death inducing kinase inhibitors with enhanced selectivity for cyclin-dependent kinases. Cancer Research. 67: 8325-34. PMID 17804748 DOI: 10.1158/0008-5472.Can-07-1826  0.417
2007 Blondel M, Meijer L. Editorial: role of cyclin-dependent kinase-5 (Cdk5) in the central nervous system. Biotechnology Journal. 2: 914-5. PMID 17680714 DOI: 10.1002/biot.200790085  0.313
2007 Reinhardt J, Ferandin Y, Meijer L. Purification of CK1 by affinity chromatography on immobilised axin. Protein Expression and Purification. 54: 101-9. PMID 17434749 DOI: 10.1016/j.pep.2007.02.020  0.321
2006 Ferandin Y, Bettayeb K, Kritsanida M, Lozach O, Polychronopoulos P, Magiatis P, Skaltsounis AL, Meijer L. 3'-Substituted 7-halogenoindirubins, a new class of cell death inducing agents. Journal of Medicinal Chemistry. 49: 4638-49. PMID 16854069 DOI: 10.1021/jm060314i  0.319
2006 Borgne A, Versteege I, Mahé M, Studeny A, Léonce S, Naime I, Rodriguez M, Hickman JA, Meijer L, Golsteyn RM. Analysis of cyclin B1 and CDK activity during apoptosis induced by camptothecin treatment. Oncogene. 25: 7361-72. PMID 16785996 DOI: 10.1038/sj.onc.1209718  0.312
2006 Beauchard A, Ferandin Y, Frère S, Lozach O, Blairvacq M, Meijer L, Thiéry V, Besson T. Synthesis of novel 5-substituted indirubins as protein kinases inhibitors. Bioorganic & Medicinal Chemistry. 14: 6434-43. PMID 16759872 DOI: 10.1016/j.bmc.2006.05.036  0.401
2006 Barluenga S, Dakas PY, Ferandin Y, Meijer L, Winssinger N. Modular asymmetric synthesis of aigialomycin D, a kinase-inhibitory scaffold. Angewandte Chemie (International Ed. in English). 45: 3951-4. PMID 16683294 DOI: 10.1002/Anie.200600593  0.31
2006 Testard A, Logé C, Léger B, Robert JM, Lozach O, Blairvacq M, Meijer L, Thiéry V, Besson T. Thiazolo[5,4-f]quinazolin-9-ones, inhibitors of glycogen synthase kinase-3. Bioorganic & Medicinal Chemistry Letters. 16: 3419-23. PMID 16644220 DOI: 10.1016/j.bmcl.2006.04.006  0.343
2006 Laurent D, Jullian V, Parenty A, Knibiehler M, Dorin D, Schmitt S, Lozach O, Lebouvier N, Frostin M, Alby F, Maurel S, Doerig C, Meijer L, Sauvain M. Antimalarial potential of xestoquinone, a protein kinase inhibitor isolated from a Vanuatu marine sponge Xestospongia sp. Bioorganic & Medicinal Chemistry. 14: 4477-82. PMID 16513357 DOI: 10.1016/j.bmc.2006.02.026  0.374
2006 Abadi AH, Abou-Seri SM, Abdel-Rahman DE, Klein C, Lozach O, Meijer L. Synthesis of 3-substituted-2-oxoindole analogues and their evaluation as kinase inhibitors, anticancer and antiangiogenic agents. European Journal of Medicinal Chemistry. 41: 296-305. PMID 16494969 DOI: 10.1016/j.ejmech.2005.12.004  0.319
2005 Wu ZL, Aryal P, Lozach O, Meijer L, Guengerich FP. Biosynthesis of new indigoid inhibitors of protein kinases using recombinant cytochrome P450 2A6. Chemistry & Biodiversity. 2: 51-65. PMID 17191919 DOI: 10.1002/Cbdv.200490166  0.31
2005 Testard A, Picot L, Lozach O, Blairvacq M, Meijer L, Murillo L, Piot JM, Thiéry V, Besson T. Synthesis and evaluation of the antiproliferative activity of novel thiazoloquinazolinone kinases inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry. 20: 557-68. PMID 16408791 DOI: 10.1080/14756360500212399  0.343
2005 Bach S, Knockaert M, Reinhardt J, Lozach O, Schmitt S, Baratte B, Koken M, Coburn SP, Tang L, Jiang T, Liang DC, Galons H, Dierick JF, Pinna LA, Meggio F, ... ... Meijer L, et al. Roscovitine targets, protein kinases and pyridoxal kinase. The Journal of Biological Chemistry. 280: 31208-19. PMID 15975926 DOI: 10.1074/Jbc.M500806200  0.376
2005 Yang H, Zheng S, Meijer L, Li SM, Leclerc S, Yu LL, Cheng JQ, Zhang SZ. Screening the active constituents of Chinese medicinal herbs as potent inhibitors of Cdc25 tyrosine phosphatase, an activator of the mitosis-inducing p34cdc2 kinase. Journal of Zhejiang University. Science. B. 6: 656-63. PMID 15973768 DOI: 10.1631/jzus.2005.B0656  0.335
2005 Kunick C, Zeng Z, Gussio R, Zaharevitz D, Leost M, Totzke F, Schächtele C, Kubbutat MH, Meijer L, Lemcke T. Structure-aided optimization of kinase inhibitors derived from alsterpaullone. Chembiochem : a European Journal of Chemical Biology. 6: 541-9. PMID 15696597 DOI: 10.1002/cbic.200400099  0.326
2005 Lu H, Chang DJ, Baratte B, Meijer L, Schulze-Gahmen U. Crystal structure of a human cyclin-dependent kinase 6 complex with a flavonol inhibitor, fisetin. Journal of Medicinal Chemistry. 48: 737-43. PMID 15689157 DOI: 10.1021/jm049353p  0.347
2005 Mapelli M, Massimiliano L, Crovace C, Seeliger MA, Tsai LH, Meijer L, Musacchio A. Mechanism of CDK5/p25 binding by CDK inhibitors. Journal of Medicinal Chemistry. 48: 671-9. PMID 15689152 DOI: 10.1021/Jm049323M  0.313
2004 Rochais C, Lescot E, Lisowski V, Lepailleur A, Santos JS, Bureau R, Dallemagne P, Meijer L, Rault S. Synthesis and biological evaluation of thienopyrrolizines, a new family of CDK/GSK-3 inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry. 19: 585-93. PMID 15662962 DOI: 10.1080/14756360400004565  0.307
2004 Grant KM, Dunion MH, Yardley V, Skaltsounis AL, Marko D, Eisenbrand G, Croft SL, Meijer L, Mottram JC. Inhibitors of Leishmania mexicana CRK3 cyclin-dependent kinase: chemical library screen and antileishmanial activity. Antimicrobial Agents and Chemotherapy. 48: 3033-42. PMID 15273118 DOI: 10.1128/AAC.48.8.3033-3042.2004  0.385
2004 Guengerich FP, Sorrells JL, Schmitt S, Krauser JA, Aryal P, Meijer L. Generation of new protein kinase inhibitors utilizing cytochrome p450 mutant enzymes for indigoid synthesis. Journal of Medicinal Chemistry. 47: 3236-41. PMID 15163202 DOI: 10.1021/Jm030561B  0.341
2004 Wan Y, Hur W, Cho CY, Liu Y, Adrian FJ, Lozach O, Bach S, Mayer T, Fabbro D, Meijer L, Gray NS. Synthesis and target identification of hymenialdisine analogs. Chemistry & Biology. 11: 247-59. PMID 15123286 DOI: 10.1016/j.chembiol.2004.01.015  0.378
2004 Knockaert M, Blondel M, Bach S, Leost M, Elbi C, Hager GL, Nagy SR, Han D, Denison M, Ffrench M, Ryan XP, Magiatis P, Polychronopoulos P, Greengard P, Skaltsounis L, ... Meijer L, et al. Independent actions on cyclin-dependent kinases and aryl hydrocarbon receptor mediate the antiproliferative effects of indirubins. Oncogene. 23: 4400-12. PMID 15077192 DOI: 10.1038/Sj.Onc.1207535  0.426
2004 Gompel M, Soulié C, Ceballos-Picot I, Meijer L. Expression and activity of cyclin-dependent kinases and glycogen synthase kinase-3 during NT2 neuronal differentiation. Neuro-Signals. 13: 134-43. PMID 15067201 DOI: 10.1159/000076567  0.361
2004 Gompel M, Leost M, De Kier Joffe EB, Puricelli L, Franco LH, Palermo J, Meijer L. Meridianins, a new family of protein kinase inhibitors isolated from the ascidian Aplidium meridianum. Bioorganic & Medicinal Chemistry Letters. 14: 1703-7. PMID 15026054 DOI: 10.1016/j.bmcl.2004.01.050  0.414
2004 Droucheau E, Primot A, Thomas V, Mattei D, Knockaert M, Richardson C, Sallicandro P, Alano P, Jafarshad A, Baratte B, Kunick C, Parzy D, Pearl L, Doerig C, Meijer L. Plasmodium falciparum glycogen synthase kinase-3: molecular model, expression, intracellular localisation and selective inhibitors. Biochimica Et Biophysica Acta. 1697: 181-96. PMID 15023360 DOI: 10.1016/j.bbapap.2003.11.023  0.324
2004 Erdogan-Orhan I, Sener B, de Rosa S, Perez-Baz J, Lozach O, Leost M, Rakhilin S, Meijer L. Polyprenyl-hydroquinones and -furans from three marine sponges inhibit the cell cycle regulating phosphatase CDC25A. Natural Product Research. 18: 1-9. PMID 14974610 DOI: 10.1080/1478641031000111534  0.386
2004 Polychronopoulos P, Magiatis P, Skaltsounis AL, Myrianthopoulos V, Mikros E, Tarricone A, Musacchio A, Roe SM, Pearl L, Leost M, Greengard P, Meijer L. Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclin-dependent kinases. Journal of Medicinal Chemistry. 47: 935-46. PMID 14761195 DOI: 10.1021/jm031016d  0.391
2003 Meijer L, Skaltsounis AL, Magiatis P, Polychronopoulos P, Knockaert M, Leost M, Ryan XP, Vonica CA, Brivanlou A, Dajani R, Crovace C, Tarricone C, Musacchio A, Roe SM, Pearl L, et al. GSK-3-selective inhibitors derived from Tyrian purple indirubins. Chemistry & Biology. 10: 1255-66. PMID 14700633 DOI: 10.1016/j.chembiol.2003.11.010  0.339
2003 Fischer PM, Endicott J, Meijer L. Cyclin-dependent kinase inhibitors. Progress in Cell Cycle Research. 5: 235-48. PMID 14593718  0.378
2003 Malgrange B, Knockaert M, Belachew S, Nguyen L, Moonen G, Meijer L, Lefebvre PP. The inhibition of cyclin-dependent kinases induces differentiation of supernumerary hair cells and Deiters' cells in the developing organ of Corti. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 17: 2136-8. PMID 12958157 DOI: 10.1096/Fj.03-0035Fje  0.334
2003 Brachwitz K, Voigt B, Meijer L, Lozach O, Schächtele C, Molnár J, Hilgeroth A. Evaluation of the first cytostatically active 1-aza-9-oxafluorenes as novel selective CDK1 inhibitors with P-glycoprotein modulating properties. Journal of Medicinal Chemistry. 46: 876-9. PMID 12593668 DOI: 10.1021/jm021090g  0.38
2003 Mettey Y, Gompel M, Thomas V, Garnier M, Leost M, Ceballos-Picot I, Noble M, Endicott J, Vierfond JM, Meijer L. Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects. Journal of Medicinal Chemistry. 46: 222-36. PMID 12519061 DOI: 10.1021/Jm020319P  0.369
2002 Biernat J, Wu YZ, Timm T, Zheng-Fischhöfer Q, Mandelkow E, Meijer L, Mandelkow EM. Protein kinase MARK/PAR-1 is required for neurite outgrowth and establishment of neuronal polarity. Molecular Biology of the Cell. 13: 4013-28. PMID 12429843 DOI: 10.1091/Mbc.02-03-0046  0.314
2002 Doerig C, Meijer L, Mottram JC. Protein kinases as drug targets in parasitic protozoa. Trends in Parasitology. 18: 366-71. PMID 12377287  0.358
2002 Knockaert M, Greengard P, Meijer L. Pharmacological inhibitors of cyclin-dependent kinases. Trends in Pharmacological Sciences. 23: 417-25. PMID 12237154 DOI: 10.1016/S0165-6147(02)02071-0  0.334
2002 Knockaert M, Lenormand P, Gray N, Schultz P, Pouysségur J, Meijer L. p42/p44 MAPKs are intracellular targets of the CDK inhibitor purvalanol. Oncogene. 21: 6413-24. PMID 12226745 DOI: 10.1038/Sj.Onc.1205908  0.322
2002 Knockaert M, Meijer L. Identifying in vivo targets of cyclin-dependent kinase inhibitors by affinity chromatography. Biochemical Pharmacology. 64: 819-25. PMID 12213575  0.354
2002 Chang YT, Choi G, Bae YS, Burdett M, Moon HS, Lee JW, Gray NS, Schultz PG, Meijer L, Chung SK, Choi KY, Suh PG, Ryu SH. Purine-based inhibitors of inositol-1,4,5-trisphosphate-3-kinase. Chembiochem : a European Journal of Chemical Biology. 3: 897-901. PMID 12210991 DOI: 10.1002/1439-7633(20020902)3:9<897::Aid-Cbic897>3.0.Co;2-B  0.341
2002 Ortega MA, Montoya ME, Zarranz B, Jaso A, Aldana I, Leclerc S, Meijer L, Monge A. Pyrazolo[3,4-b]quinoxalines. A new class of cyclin-dependent kinases inhibitors. Bioorganic & Medicinal Chemistry. 10: 2177-84. PMID 11983514  0.405
2002 Knockaert M, Wieking K, Schmitt S, Leost M, Grant KM, Mottram JC, Kunick C, Meijer L. Intracellular Targets of Paullones. Identification following affinity purification on immobilized inhibitor. The Journal of Biological Chemistry. 277: 25493-501. PMID 11964410 DOI: 10.1074/jbc.M202651200  0.307
2002 Schoepfer J, Fretz H, Chaudhuri B, Muller L, Seeber E, Meijer L, Lozach O, Vangrevelinghe E, Furet P. Structure-based design and synthesis of 2-benzylidene-benzofuran-3-ones as flavopiridol mimics. Journal of Medicinal Chemistry. 45: 1741-7. PMID 11960485  0.309
2001 Loukaci A, Le Saout I, Samadi M, Leclerc S, Damiens E, Meijer L, Debitus C, Guyot M. Coscinosulfate, a CDC25 phosphatase inhibitor from the sponge Coscinoderma mathewsi. Bioorganic & Medicinal Chemistry. 9: 3049-54. PMID 11597488  0.375
2001 Damiens E, Baratte B, Marie D, Eisenbrand G, Meijer L. Anti-mitotic properties of indirubin-3'-monoxime, a CDK/GSK-3 inhibitor: induction of endoreplication following prophase arrest. Oncogene. 20: 3786-97. PMID 11439342 DOI: 10.1038/sj.onc.1204503  0.34
2001 Harmse L, van Zyl R, Gray N, Schultz P, Leclerc S, Meijer L, Doerig C, Havlik I. Structure-activity relationships and inhibitory effects of various purine derivatives on the in vitro growth of Plasmodium falciparum. Biochemical Pharmacology. 62: 341-8. PMID 11434907 DOI: 10.1016/S0006-2952(01)00644-X  0.353
2001 Davies TG, Tunnah P, Meijer L, Marko D, Eisenbrand G, Endicott JA, Noble ME. Inhibitor binding to active and inactive CDK2: the crystal structure of CDK2-cyclin A/indirubin-5-sulphonate. Structure (London, England : 1993). 9: 389-97. PMID 11377199  0.332
2001 Meijer L, Knockaert M, Damiens E. [Prevention of chemotherapy-induced alopecia by cyclin-dependant kinase inhibitors]. Bulletin Du Cancer. 88: 347-50. PMID 11371368  0.36
2001 Dorin D, Le Roch K, Sallicandro P, Alano P, Parzy D, Poullet P, Meijer L, Doerig C. Pfnek-1, a NIMA-related kinase from the human malaria parasite Plasmodium falciparum Biochemical properties and possible involvement in MAPK regulation. European Journal of Biochemistry / Febs. 268: 2600-8. PMID 11322879 DOI: 10.1046/j.1432-1327.2001.02151.x  0.406
2001 Leclerc S, Garnier M, Hoessel R, Marko D, Bibb JA, Snyder GL, Greengard P, Biernat J, Wu YZ, Mandelkow EM, Eisenbrand G, Meijer L. Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors? The Journal of Biological Chemistry. 276: 251-60. PMID 11013232 DOI: 10.1074/jbc.M002466200  0.354
2000 Andreani A, Cavalli A, Granaiola M, Leoni A, Locatelli A, Morigi R, Rambaldi M, Recanatini M, Garnier M, Meijer L. Imidazo[2,1 -b]thiazolylmethylene- and indolylmethylene-2-indolinones: a new class of cyclin-dependent kinase inhibitors. Design, synthesis, and CDK1/cyclin B inhibition. Anti-Cancer Drug Design. 15: 447-52. PMID 11716438  0.375
2000 Meijer L. Cyclin-dependent kinases inhibitors as potential anticancer, antineurodegenerative, antiviral and antiparasitic agents. Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy. 3: 83-88. PMID 11498372 DOI: 10.1054/drup.2000.0129  0.338
2000 Primot A, Baratte B, Gompel M, Borgne A, Liabeuf S, Romette JL, Jho EH, Costantini F, Meijer L. Purification of GSK-3 by affinity chromatography on immobilized axin. Protein Expression and Purification. 20: 394-404. PMID 11087679 DOI: 10.1006/Prep.2000.1321  0.319
2000 Leost M, Schultz C, Link A, Wu YZ, Biernat J, Mandelkow EM, Bibb JA, Snyder GL, Greengard P, Zaharevitz DW, Gussio R, Senderowicz AM, Sausville EA, Kunick C, Meijer L. Paullones are potent inhibitors of glycogen synthase kinase-3beta and cyclin-dependent kinase 5/p25. European Journal of Biochemistry / Febs. 267: 5983-94. PMID 10998059 DOI: 10.1046/j.1432-1327.2000.01673.x  0.367
2000 Jeong HW, Kim MR, Son KH, Han MY, Ha JH, Garnier M, Meijer L, Kwon BM. Cinnamaldehydes inhibit cyclin dependent kinase 4/cyclin D1. Bioorganic & Medicinal Chemistry Letters. 10: 1819-22. PMID 10969976 DOI: 10.1016/S0960-894X(00)00357-7  0.354
2000 Knockaert M, Gray N, Damiens E, Chang YT, Grellier P, Grant K, Fergusson D, Mottram J, Soete M, Dubremetz JF, Le Roch K, Doerig C, Schultz P, Meijer L. Intracellular targets of cyclin-dependent kinase inhibitors: identification by affinity chromatography using immobilised inhibitors. Chemistry & Biology. 7: 411-22. PMID 10873834 DOI: 10.1016/S1074-5521(00)00124-1  0.378
2000 Damiens E, Meijer L. [Chemical inhibitors of cyclic-dependent kinases: preclinical and clinical study]. Pathologie-Biologie. 48: 340-51. PMID 10858966  0.329
2000 Legraverend M, Tunnah P, Noble M, Ducrot P, Ludwig O, Grierson DS, Leost M, Meijer L, Endicott J. Cyclin-dependent kinase inhibition by new C-2 alkynylated purine derivatives and molecular structure of a CDK2-inhibitor complex. Journal of Medicinal Chemistry. 43: 1282-92. PMID 10753466 DOI: 10.1021/Jm9911130  0.309
2000 Le Roch K, Sestier C, Dorin D, Waters N, Kappes B, Chakrabarti D, Meijer L, Doerig C. Activation of a Plasmodium falciparum cdc2-related kinase by heterologous p25 and cyclin H. Functional characterization of a P. falciparum cyclin homologue. The Journal of Biological Chemistry. 275: 8952-8. PMID 10722743  0.365
2000 Meijer L, Thunnissen AM, White AW, Garnier M, Nikolic M, Tsai LH, Walter J, Cleverley KE, Salinas PC, Wu YZ, Biernat J, Mandelkow EM, Kim SH, Pettit GR. Inhibition of cyclin-dependent kinases, GSK-3beta and CK1 by hymenialdisine, a marine sponge constituent. Chemistry & Biology. 7: 51-63. PMID 10662688 DOI: 10.1016/S1074-5521(00)00063-6  0.415
2000 Mermillod P, Tomanek M, Marchal R, Meijer L. High developmental competence of cattle oocytes maintained at the germinal vesicle stage for 24 hours in culture by specific inhibition of MPF kinase activity. Molecular Reproduction and Development. 55: 89-95. PMID 10602278 DOI: 10.1002/(SICI)1098-2795(200001)55:1<89::AID-MRD12>3.0.CO;2-M  0.308
1999 Giocanti N, Sadri R, Legraverend M, Ludwig O, Bisagni E, Leclerc S, Meijer L, Favaudon V. In vitro evaluation of a novel 2,6,9-trisubstituted purine acting as a cyclin-dependent kinase inhibitor. Annals of the New York Academy of Sciences. 886: 180-2. PMID 10667214  0.384
1999 Bibb JA, Snyder GL, Nishi A, Yan Z, Meijer L, Fienberg AA, Tsai LH, Kwon YT, Girault JA, Czernik AJ, Huganir RL, Hemmings HC, Nairn AC, Greengard P. Phosphorylation of DARPP-32 by Cdk5 modulates dopamine signalling in neurons. Nature. 402: 669-71. PMID 10604473 DOI: 10.1038/45251  0.404
1999 Hoessel R, Leclerc S, Endicott JA, Nobel ME, Lawrie A, Tunnah P, Leost M, Damiens E, Marie D, Marko D, Niederberger E, Tang W, Eisenbrand G, Meijer L. Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nature Cell Biology. 1: 60-7. PMID 10559866 DOI: 10.1038/9035  0.356
1999 Gray N, Détivaud L, Doerig C, Meijer L. ATP-site directed inhibitors of cyclin-dependent kinases. Current Medicinal Chemistry. 6: 859-75. PMID 10495356  0.352
1999 Legraverend M, Ludwig O, Bisagni E, Leclerc S, Meijer L, Giocanti N, Sadri R, Favaudon V. Synthesis and in vitro evaluation of novel 2,6,9-trisubstituted purines acting as cyclin-dependent kinase inhibitors. Bioorganic & Medicinal Chemistry. 7: 1281-93. PMID 10465404  0.312
1999 Sausville EA, Zaharevitz D, Gussio R, Meijer L, Louarn-Leost M, Kunick C, Schultz R, Lahusen T, Headlee D, Stinson S, Arbuck SG, Senderowicz A. Cyclin-dependent kinases: initial approaches to exploit a novel therapeutic target. Pharmacology & Therapeutics. 82: 285-92. PMID 10454206  0.318
1999 Meijer L, Leclerc S, Leost M. Properties and potential-applications of chemical inhibitors of cyclin-dependent kinases. Pharmacology & Therapeutics. 82: 279-84. PMID 10454205  0.322
1999 Détivaud L, Pettit GR, Meijer L. Characterization of a novel cdk1-related kinase. European Journal of Biochemistry / Febs. 264: 55-66. PMID 10447673 DOI: 10.1046/J.1432-1327.1999.00576.X  0.413
1999 Schultz C, Link A, Leost M, Zaharevitz DW, Gussio R, Sausville EA, Meijer L, Kunick C. Paullones, a series of cyclin-dependent kinase inhibitors: synthesis, evaluation of CDK1/cyclin B inhibition, and in vitro antitumor activity. Journal of Medicinal Chemistry. 42: 2909-19. PMID 10425100 DOI: 10.1021/jm9900570  0.328
1999 Chang YT, Gray NS, Rosania GR, Sutherlin DP, Kwon S, Norman TC, Sarohia R, Leost M, Meijer L, Schultz PG. Synthesis and application of functionally diverse 2,6,9-trisubstituted purine libraries as CDK inhibitors. Chemistry & Biology. 6: 361-75. PMID 10375538 DOI: 10.1016/S1074-5521(99)80048-9  0.333
1999 Zaharevitz DW, Gussio R, Leost M, Senderowicz AM, Lahusen T, Kunick C, Meijer L, Sausville EA. Discovery and initial characterization of the paullones, a novel class of small-molecule inhibitors of cyclin-dependent kinases. Cancer Research. 59: 2566-9. PMID 10363974  0.346
1999 Borgne A, Ostvold AC, Flament S, Meijer L. Intra-M phase-promoting factor phosphorylation of cyclin B at the prophase/metaphase transition. The Journal of Biological Chemistry. 274: 11977-86. PMID 10207019  0.331
1998 Legraverend M, Ludwig O, Bisagni E, Leclerc S, Meijer L. Synthesis of C2 alkynylated purines, a new family of potent inhibitors of cyclin-dependent kinases. Bioorganic & Medicinal Chemistry Letters. 8: 793-8. PMID 9871543  0.337
1998 Alessi F, Quarta S, Savio M, Riva F, Rossi L, Stivala LA, Scovassi AI, Meijer L, Prosperi E. The cyclin-dependent kinase inhibitors olomoucine and roscovitine arrest human fibroblasts in G1 phase by specific inhibition of CDK2 kinase activity. Experimental Cell Research. 245: 8-18. PMID 9828096 DOI: 10.1006/excr.1998.4216  0.374
1998 Gray NS, Wodicka L, Thunnissen AM, Norman TC, Kwon S, Espinoza FH, Morgan DO, Barnes G, LeClerc S, Meijer L, Kim SH, Lockhart DJ, Schultz PG. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science (New York, N.Y.). 281: 533-8. PMID 9677190 DOI: 10.1126/Science.281.5376.533  0.353
1997 An B, Dineley K, Zhang L, Termin T, Meijer L, Dou Q. Involvement of RB kinases and phosphatases in life and death decisions. Oncology Reports. 4: 1129-34. PMID 21590208 DOI: 10.3892/Or.4.6.1129  0.401
1997 Pippin JW, Qu Q, Meijer L, Shankland SJ. Direct in vivo inhibition of the nuclear cell cycle cascade in experimental mesangial proliferative glomerulonephritis with Roscovitine, a novel cyclin-dependent kinase antagonist. The Journal of Clinical Investigation. 100: 2512-20. PMID 9366565 DOI: 10.1172/JCI119793  0.349
1997 Krucher NA, Meijer L, Roberts MH. The cyclin-dependent kinase (cdk) inhibitors, olomoucine and roscovitine, alter the expression of a molluscan circadian pacemaker. Cellular and Molecular Neurobiology. 17: 495-507. PMID 9353591  0.344
1997 Schutte B, Nieland L, van Engeland M, Henfling ME, Meijer L, Ramaekers FC. The effect of the cyclin-dependent kinase inhibitor olomoucine on cell cycle kinetics. Experimental Cell Research. 236: 4-15. PMID 9344580 DOI: 10.1006/excr.1997.3700  0.352
1997 Meijer L, Kim SH. Chemical inhibitors of cyclin-dependent kinases. Methods in Enzymology. 283: 113-28. PMID 9251015 DOI: 10.1016/S0076-6879(97)83011-X  0.36
1997 Havlícek L, Hanus J, Veselý J, Leclerc S, Meijer L, Shaw G, Strnad M. Cytokinin-derived cyclin-dependent kinase inhibitors: synthesis and cdc2 inhibitory activity of olomoucine and related compounds. Journal of Medicinal Chemistry. 40: 408-12. PMID 9046330 DOI: 10.1021/jm960666x  0.356
1997 Meijer L, Borgne A, Mulner O, Chong JP, Blow JJ, Inagaki N, Inagaki M, Delcros JG, Moulinoux JP. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. European Journal of Biochemistry / Febs. 243: 527-36. PMID 9030781 DOI: 10.1111/J.1432-1033.1997.T01-2-00527.X  0.423
1997 De Azevedo WF, Leclerc S, Meijer L, Havlicek L, Strnad M, Kim SH. Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine. European Journal of Biochemistry / Febs. 243: 518-26. PMID 9030780  0.34
1996 Meijer L. Chemical inhibitors of cyclin-dependent kinases. Trends in Cell Biology. 6: 393-7. PMID 15157522  0.36
1996 Borgne A, Meijer L. Sequential dephosphorylation of p34(cdc2) on Thr-14 and Tyr-15 at the prophase/metaphase transition. The Journal of Biological Chemistry. 271: 27847-54. PMID 8910383  0.352
1995 Meijer L. Chemical inhibitors of cyclin-dependent kinases. Progress in Cell Cycle Research. 1: 351-63. PMID 9552377  0.36
1995 Schulze-Gahmen U, Brandsen J, Jones HD, Morgan DO, Meijer L, Vesely J, Kim SH. Multiple modes of ligand recognition: crystal structures of cyclin-dependent protein kinase 2 in complex with ATP and two inhibitors, olomoucine and isopentenyladenine. Proteins. 22: 378-91. PMID 7479711 DOI: 10.1002/Prot.340220408  0.35
1994 Azzi L, Meijer L, Ostvold AC, Lew J, Wang JH. Purification of a 15-kDa cdk4- and cdk5-binding protein. The Journal of Biological Chemistry. 269: 13279-88. PMID 8175758  0.343
1992 Baratte B, Meijer L, Galaktionov K, Beach D. Screening for antimitotic compounds using the cdc25 tyrosine phosphatase, an activator of the mitosis-inducing p34cdc2/cyclin Bcdc13 protein kinase. Anticancer Research. 12: 873-80. PMID 1320360  0.376
1991 Meijer L, Ostvold AC, Walass SI, Lund T, Laland SG. High-mobility-group proteins P1, I and Y as substrates of the M-phase-specific p34cdc2/cyclincdc13 kinase. European Journal of Biochemistry / Febs. 196: 557-67. PMID 2013279  0.365
1991 Meijer L, Arion D. Negative control of cdc2 kinase activation by cAMP in starfish oocytes. Cold Spring Harbor Symposia On Quantitative Biology. 56: 591-8. PMID 1668090  0.345
1990 Pondaven P, Meijer L, Beach D. Activation of M-phase-specific histone H1 kinase by modification of the phosphorylation of its p34cdc2 and cyclin components. Genes & Development. 4: 9-17. PMID 2155162  0.309
1989 Meijer L, Arion D, Golsteyn R, Pines J, Brizuela L, Hunt T, Beach D. Cyclin is a component of the sea urchin egg M-phase specific histone H1 kinase. The Embo Journal. 8: 2275-82. PMID 2551679  0.324
1989 Arion D, Meijer L. M-phase-specific protein kinase from mitotic sea urchin eggs: cyclic activation depends on protein synthesis and phosphorylation but does not require DNA or RNA synthesis. Experimental Cell Research. 183: 361-75. PMID 2475356  0.328
1988 Pelech SL, Tombes RM, Meijer L, Krebs EG. Activation of myelin basic protein kinases during echinoderm oocyte maturation and egg fertilization. Developmental Biology. 130: 28-36. PMID 3181631 DOI: 10.1016/0012-1606(88)90410-1  0.355
1988 Meijer L, Pondaven P. Cyclic activation of histone H1 kinase during sea urchin egg mitotic divisions. Experimental Cell Research. 174: 116-29. PMID 2826194  0.382
1987 Meijer L, Pelech SL, Krebs EG. Differential regulation of histone H1 and ribosomal S6 kinases during sea star oocyte maturation. Biochemistry. 26: 7968-74. PMID 2827766 DOI: 10.1021/Bi00398A063  0.365
1982 Meijer L, Paul M, Epel D. Stimulation of protein phosphorylation during fertilization-induced maturation of Urechis caupo oocytes. Developmental Biology. 94: 62-70. PMID 6295850 DOI: 10.1016/0012-1606(82)90068-9  0.556
Show low-probability matches.